Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas

被引:115
作者
Fujisawa, H
Reis, RM
Nakamura, M
Colella, S
Yonekawa, Y
Kleihues, P
Ohgaki, H
机构
[1] Int Agcy Res Canc, Unit Mol Pathol, F-69372 Lyon 08, France
[2] Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland
关键词
D O I
10.1038/labinvest.3780009
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR and MDM2 amplification/overexpression, PTEN mutations, and p16 deletions, whereas secondary glioblastomas frequently contain p53 mutations. Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis. LOH#10 was detected at similar frequencies in primary (8/17; 47%) and secondary glioblastomas (7/13; 54%). The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10. In contrast, secondary glioblastomas with LOH#10 showed partial or complete loss of chromosome 10q but no loss of 10p. These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 62 条
[1]  
Albarosa R, 1996, AM J HUM GENET, V58, P1260
[2]  
Boström J, 1998, CANCER RES, V58, P29
[3]  
BRUSTLE O, 1992, CANCER, V69, P2385, DOI 10.1002/1097-0142(19920501)69:9<2385::AID-CNCR2820690929>3.0.CO
[4]  
2-3
[5]   Characterization of MAD2B and other mitotic spindle checkpoint genes [J].
Cahill, DP ;
da Costa, LT ;
Carson-Walter, EB ;
Kinzler, KW ;
Vogelstein, B ;
Lengauer, C .
GENOMICS, 1999, 58 (02) :181-187
[6]  
Cairns P, 1997, CANCER RES, V57, P4997
[7]   A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors [J].
Chernova, OB ;
Somerville, RPT ;
Cowell, JK .
ONCOGENE, 1998, 17 (22) :2873-2881
[8]   PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas [J].
Chiariello, E ;
Roz, L ;
Albarosa, R ;
Magnani, I ;
Finocchiaro, G .
ONCOGENE, 1998, 16 (04) :541-545
[9]   A metric map of humans: 23,500 loci in 850 bands [J].
Collins, A ;
Frezal, J ;
Teague, J ;
Morton, NE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14771-14775
[10]   PTEN mutations in gliomas and glioneuronal tumors [J].
Duerr, EM ;
Rollbrocker, B ;
Hayashi, Y ;
Peters, N ;
Meyer-Puttlitz, B ;
Louis, DN ;
Schramm, J ;
Wiestler, OD ;
Parsons, R ;
Eng, C ;
von Deimling, A .
ONCOGENE, 1998, 16 (17) :2259-2264